GENERAL COMMENTS
This is a post-hoc analysis of the Copenhagen Hospital Heart Failure Study, published previously. This study is timely and of interest. The major findings are that proANP levels predict mortality in patients presenting with acute diseases to the hospital /emergency department.
Some concerns remain and should be addressed: 1) Plasma sample have been stored for more then 10 years at -20°C. What about the stability of the analyte.
2) I have some concerns regarding the statistical analysis of the study. Possibly, the analysis should be reviewed by a statistician. I for myself have following questions/suggestions: a) Why have the authors used quartiles for univariate and multivariable analysis. Usually, levels of natriuretic peptides have been included after log-transformation. I believe that the graphical demonstration of quartiles are useful for presentation. However, direct inclusion of log-transformed values should be made.
b) The Charlson Comorbidity Index is an established risk stratification tool for prediction of mortality in an unselected cohort of patients. I would suggest to use this model for statistical analysis and presentation of data.
3) A major weakness of the present study could be that the diagnosis of heart failure has considerably be changed during recent years. The authors used a definition of heart failure as used at the end of the 1990 and beginning of 2000. Therefore I speculate that higher proANP are an indicator of "undetected" heart failure especially in elderly people (significant older people in quartile 4). Thus, the interpretation of the major results of this study could be that higher proANP levels are associated with the presence of heart failure in an elderly population of patients presenting with other comorbid conditions to the hospital. This concern should be discussed.
Minor points:
1) eGFR cannot be used in patients presenting with acute disease (Bragadottir G, Redfors B, Ricksten SE. Crit Care. 2013) 2) The inclusion criteria for this cohort should be shortly given in the method section.
The sample size is adequate, the complete and long follow-up are strengths. Nevertheless, there remain some critical points.
Comments:
1.) Why was a linear regression used for statistical analysis of group differences (between proANP quartiles) of baseline characteristics ( 
This is a interesting study on ProANP and all-cause mortality in acultely hospitalised patients. The study is based on 1337 participants out of 1255 were acutely hospitalised.
The study is well written. But I do have some major problems with the study. The abstract is well written but lacks some basic information which when included will make it much easier for the reader.
In the abstract values for the ProANP quartiles should be added.
When adjusting for multivariate model please all the variates the model is adjusted for as it is hard to read to different sections to find as to what the multivariate model was.
In the conclusions´section of the abstract all of a sudden NT-proBNP is mentioned. This should be mentioned in the objective and the results as well.
In the Design and Study population section the authors mentioned that 80% of the subjects (n=2230) where does this number come from similarly 2193 had a satisfactory echo. This number is not mentioned in the abstarct. Please clarify. My major concern is that the authors did not adjusted for body mass index, hypertension, serum creatinine levels and cholesterol in the multivariate model which are the most important risk factors for CVD. At the same time this was not mentioned in the limitations of the study. This would have to some extent changed the results. If there is no information on these risk factors, it should be mentioned in the limiations of the study.
Would have liked to see a multivariate model further adjusted for various medications.
VERSION 1 -AUTHOR RESPONSE
Reviewer: Michael Christ, M.D., Head of the Department of Emergency and Critical Care Medicine, Nuremberg, Germany
Thank you for the opportunity to review this interesting manuscript on the value of proANP levels to predict mortality in a unselected cohort of patients presenting to the hospital. This is a post-hoc analysis of the Copenhagen Hospital Heart Failure Study, published previously. This study is timely and of interest. The major findings are that proANP levels predict mortality in patients presenting with acute diseases to the hospital /emergency department.
Reply: We agree that this is relevant information. As for comment one, we used a processingindependent proANP assay that requires pre-treatment with trypsin in order to release the measured epitope to plasma. In this way, the assay is extremely robust in terms of analyte stability. We have included some information on this including a review on the assay technology (new reference 15). As for comment two and a); we have included the requested results in the manuscript and supplemental material.
Reply: We agree that the Charlson Comorbidity Index (CC index) would be of interest regarding mortality. However, we do not have sufficient data to calculate the index for all participants. Furthermore, since the index would have to be calculated primarily on the admission diagnosis (most data), there would be a considerable risk of misclassification.
The index also seems to be most predictive regarding inpatient mortality and less effective when predicting short-term mortality, with limited literature available on long-term mortality (Journal of Critical Care (2005) 20,12-19).
Reply: This is a highly relevant comment. I terms of the heart failure diagnosis, this was the prevailing model at the time of study. To make the concern readily available to the readership, we have included a new (brief) section in the discussion, where we note that proANP measurement also may reflect undetected heart failure in the elderly population.
Minor points: 1) eGFR cannot be used in patients presenting with acute disease (Bragadottir G, Redfors B, Ricksten SE. Crit Care. 2013)
Reply: We fully agree that eGFR is difficult to interpret in an acute setting. We, however, primarily use the eGFR in an epidemiologically setting to adjust for confounding. Of note, using creatinine measures in the multivariable analysis did not alter the results significantly.
2) The inclusion criteria for this cohort should be shortly given in the method section.
Reply: We have included a brief description of the inclusion criteria in the method section.
Reviewer: Olli Vuolteenaho, Professor Institute of Biomedicine, University of Oulu Finland -no competing interests
The nomenclature may be confusing: as very little actual proANP can be found in the circulation, proANP in fact refers to the N-terminal fragment of proANP, or am I mistaken?
Reply: The proANP measurement is based on a so-called processing-independent assay, where the epitope is released after trypsin treatment of the samples. The epitope is indeed released from the Nterminal fragment, but the measurement reflect overall translational products in plasma regardless of processing. We have included some more information on the assay and a new reference on the subject (new reference 15).
-In my experience there are two conditions that can lead to greatly elevated proANP concentrations (corresponding to those in the 4th quartile of the present ms): significantly decreased pump function of the heart or significantly decreased kidney function. I don't think that the question of kidney function has been adequately addressed. eGFR is not an ideal marker of this. Has it been ruled out that proANP only serves as a fancy kidney function test here?
Reply: We agree that kidney function could be a potential confounder in the analysis. However we do not think that this is the case for several reasons: 1) The correlation between creatinine (and hence eGFR) and proANP is very modest in this cohort (R2 of 0.19 and 0.20 respectively).
2) The mean eGFR in quartile 4, although lower than the other quartiles, are still markedly higher than 30 ml/min. A possible effect from kidney function on proANP concentrations seems to be primarily evident at GFR below 30 mL/min in previous studies 3) Adjusting for eGFR (or creatinine) did not change the results. 4) No interaction was seen between proANP and creatinine or eGFR on endpoints (Smallest P≥0.15).
-It is curious why the reported eGFRs in the supplemental tables 1 to 4 are always precisely 1.00 (to two decimal places!), without any significant variation (all the other parameters vary and display realistic variance). It appears as if the data were normalized to eFR, but I cannot find any description of this.
Reply: We agree that the small HRs for eGFR may appear peculiar. The HRs for the eGFRs in the Cox models reflects 1 unit of change in eGFR. Therefore, a corresponding increase in HR is small (measured on the third decimal) since the scale for eGFR is large. Categorising the eGFR variable would yield a more notable effect, but this would be at the cost of power. Since eGFR is used primarily for adjustment in the statistical analysis, we chose to test the maximum effect of this variable.
-The ms is descriptive and the practical importance of the results seems not clear to me ("so what?").
The authors should present some short of analysis/discussion in the spirit of "number needed to screen": average number of patients who need to be screened to detect (and then prevent?) one additional bad outcome. I'm a little confused as to e.g. should a patient in the 4th quartile be treated differently from the others, and how?
Reply: Our study is observational in its nature. We are not in agreement with the -so what‖ conclusion, as the study is the first of its kind to use proANP measurement at admission to a general hospital without prior or post-hoc patient selection. Some new discussion on what the increased proANP concentrations might reflect has now been included, where the possibility of unrecognized heart failure has been highlighted (which makes some suggestions on -what to do‖). We believe a discussion on number needed to screen would be premature and beyond the space limits for original manuscripts.
- Reply: We agree that there have been other reports of natriuretic peptides and all cause mortality. However, as stated in the introduction and the discussion, they were primarily descriptive in preselected patient cohorts. Compared to these narrowly defined patient populations (intensive care patients, cardiac patients etc.) our cohort reflects typical patients seen in internal medicine and general surgery. Our study thus expands on the potential use of natriuretic peptide measurement into a much broader population of hospitalized patients. No competing interests
In their study -ProANP plasma measurement predicts all cause mortality in acutely hospitalised patients‖ Lauridsen et al. show a significant association between the highest quartile of proANP/NTproBNP and all-cause mortality in the short (1 year) and long term.
1.) Why was a linear regression used for statistical analysis of group differences (between proANP quartiles) of baseline characteristics (Table 1) ? For continuous variables I would recommend ANOVA.
Reply: We have recalculated the P values using ANOVA and amended them to the manuscript. Reply: eGFR was calculated using MDRD. There is a modest correlation between proANP, proBNP and eGFR (R2 0.20 and 0.10 respectively). Adding eGFR to the reduced models in the primary analysis did not alter the results (HRs 2.53 and 2.02 for short and long-term mortality for proANP in the fourth quartile -similar for proBNP).
3.) Apart from modelling mortality risk using quartiles, the risk association of proANP and NT-proBNP as continuous variable in the Cox regression model would be of interest.
Reply: We agree that this is relevant information and have included these results in the manuscript and the supplemental material.
4.) Authors state that the risk -association persisted in participants with seemingly normal cardiac function‖. This statement refers to echocardiographic evaluation of systolic LVF (LVEF>50%) and cardiac history at baseline. Do the authors have data about diastolic function and RV function?
Reply: Unfortunately, we have limited to no information on diastolic and right ventricular function. We chose to use a simple, reproducible measurement of myocardial function since the present equipment did not allow for additional detailed measurement of cardiac function.
5.) What is or could be the mechanism of increased mortality risk with higher proANP levels? It is absolutely not sufficient to state that -the biological explanations for the observed association between increased proANP concentrations and mortality in the present study are numerous‖; please detail these explanations with adequate references. Do the authors have data about the death causes? Was their a difference in cardiovascular and non-cardiovascular deaths dependent on proANP?
Reply: We have included a new section in the discussion on what increased proANP might entail in terms of disease. In principal, we suspect that the at least some patients might in fact suffer from unrecognized heart failure -or other cardiac diagnoses including left ventricular hypertrophy.
6.) As a limitation of the study the single baseline measurement should be mentioned, as there were no time-dependent measurements. It is questionable why and how a biochemical marker measured 11 years before should/could influence later mortality risk.
Reply: We agree that lack of time-dependent covariates is a limitation and have added this to the manuscript. However the peptide concentrations probably reflect incipient as well as documented heart damage, which is largely an inevitable pathophysiological pathway to increased mortality. We therefore believe that this is reflected in the elevated natriuretic pathway even across a relative large timescale, which has also been documented elsewhere (JAMA, May 25, 2011-Vol 305, No. 20) .
7.) In the Abstract please rephrase the -Objective‖, e.g. -To test the risk association between proANP and short-and long-term mortality and its predictive value in acutely hospitalised patients‖ or similar. Instead of -Most of the effect seemed to associate with the highest ……‖ authors should emphasize that it was the forth quartile that was associated with increased all-cause mortality. The conclusion that -…using proANP or a combination of proANP and NT-proBNP could lend vital support in the evaluation of acutely hospitalised patients‖ is not clear; what do authors mean with that? In which way?
